 Luisa Mestroni
Concepts (570)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Dilated | 88 | 2023 | 346 | 10.000 |
Why?
| | Cardiomyopathies | 36 | 2023 | 300 | 6.240 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 23 | 2023 | 35 | 5.880 |
Why?
| | Arrhythmias, Cardiac | 31 | 2023 | 279 | 4.200 |
Why?
| | Myocytes, Cardiac | 25 | 2023 | 448 | 3.850 |
Why?
| | Heart Failure | 32 | 2023 | 1952 | 2.690 |
Why?
| | Lamin Type A | 18 | 2023 | 40 | 2.650 |
Why?
| | Mutation | 40 | 2023 | 3353 | 1.950 |
Why?
| | Cardiomyopathy, Hypertrophic | 14 | 2023 | 122 | 1.900 |
Why?
| | Myocardium | 23 | 2023 | 911 | 1.800 |
Why?
| | Nanotubes, Carbon | 6 | 2022 | 43 | 1.740 |
Why?
| | Tissue Engineering | 7 | 2023 | 364 | 1.620 |
Why?
| | Muscle Proteins | 7 | 2020 | 210 | 1.450 |
Why?
| | Death, Sudden, Cardiac | 18 | 2023 | 160 | 1.450 |
Why?
| | Phenotype | 31 | 2023 | 2817 | 1.420 |
Why?
| | Genetic Predisposition to Disease | 22 | 2023 | 2102 | 1.370 |
Why?
| | Filamins | 5 | 2023 | 19 | 1.340 |
Why?
| | Genetic Variation | 6 | 2021 | 876 | 1.260 |
Why?
| | Tissue Scaffolds | 6 | 2022 | 179 | 1.250 |
Why?
| | Electrocardiography | 17 | 2023 | 562 | 1.250 |
Why?
| | Cell Adhesion | 11 | 2021 | 430 | 1.110 |
Why?
| | Heart | 10 | 2021 | 609 | 1.100 |
Why?
| | Genetic Testing | 13 | 2021 | 379 | 1.100 |
Why?
| | Sarcomeres | 6 | 2021 | 90 | 0.980 |
Why?
| | Humans | 185 | 2023 | 114935 | 0.980 |
Why?
| | Fibroblasts | 5 | 2022 | 839 | 0.980 |
Why?
| | Connectin | 10 | 2022 | 30 | 0.980 |
Why?
| | Precision Medicine | 5 | 2020 | 339 | 0.940 |
Why?
| | Pharmacogenetics | 5 | 2014 | 149 | 0.900 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2023 | 8 | 0.900 |
Why?
| | Glycogen Storage Disease Type IIb | 7 | 2021 | 22 | 0.870 |
Why?
| | Heart Ventricles | 13 | 2021 | 711 | 0.820 |
Why?
| | Mutation, Missense | 9 | 2021 | 295 | 0.810 |
Why?
| | Pedigree | 29 | 2021 | 467 | 0.790 |
Why?
| | Gold | 3 | 2020 | 106 | 0.770 |
Why?
| | Induced Pluripotent Stem Cells | 3 | 2023 | 182 | 0.740 |
Why?
| | Microscopy, Atomic Force | 11 | 2022 | 113 | 0.740 |
Why?
| | Genetic Therapy | 2 | 2017 | 258 | 0.690 |
Why?
| | Prognosis | 19 | 2022 | 3344 | 0.690 |
Why?
| | Metal Nanoparticles | 2 | 2020 | 75 | 0.650 |
Why?
| | Ventricular Remodeling | 4 | 2023 | 227 | 0.640 |
Why?
| | Ventricular Dysfunction, Left | 7 | 2023 | 360 | 0.640 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2022 | 59 | 0.610 |
Why?
| | Dystrophin | 10 | 2020 | 30 | 0.610 |
Why?
| | Plakophilins | 4 | 2023 | 5 | 0.590 |
Why?
| | Ventricular Function | 1 | 2017 | 56 | 0.580 |
Why?
| | Male | 86 | 2023 | 55663 | 0.570 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2016 | 3 | 0.560 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2016 | 19 | 0.560 |
Why?
| | Middle Aged | 55 | 2023 | 26806 | 0.530 |
Why?
| | Laminin | 1 | 2016 | 69 | 0.530 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 250 | 0.520 |
Why?
| | Biomimetics | 1 | 2016 | 36 | 0.520 |
Why?
| | Protein Kinases | 4 | 2013 | 307 | 0.520 |
Why?
| | Registries | 15 | 2023 | 1760 | 0.510 |
Why?
| | Defibrillators, Implantable | 4 | 2021 | 286 | 0.510 |
Why?
| | Hydrogels | 2 | 2019 | 573 | 0.510 |
Why?
| | Embryonic Stem Cells | 1 | 2016 | 105 | 0.510 |
Why?
| | Female | 82 | 2023 | 59580 | 0.500 |
Why?
| | Cell Adhesion Molecules | 2 | 2023 | 168 | 0.500 |
Why?
| | Adult | 60 | 2023 | 30608 | 0.500 |
Why?
| | Polymers | 4 | 2022 | 447 | 0.500 |
Why?
| | DNA Mutational Analysis | 11 | 2018 | 372 | 0.500 |
Why?
| | Genetic Heterogeneity | 2 | 2009 | 49 | 0.490 |
Why?
| | Stroke Volume | 13 | 2023 | 510 | 0.490 |
Why?
| | Rats | 12 | 2022 | 4963 | 0.490 |
Why?
| | Ventricular Function, Left | 9 | 2023 | 468 | 0.490 |
Why?
| | Animals | 36 | 2023 | 31837 | 0.480 |
Why?
| | Receptors, Endothelin | 2 | 2014 | 49 | 0.480 |
Why?
| | Ventricular Dysfunction, Right | 4 | 2023 | 218 | 0.470 |
Why?
| | Receptors, Adrenergic | 1 | 2014 | 35 | 0.460 |
Why?
| | Lysine | 1 | 2016 | 242 | 0.460 |
Why?
| | Connexin 43 | 1 | 2014 | 23 | 0.460 |
Why?
| | Echocardiography | 10 | 2021 | 555 | 0.440 |
Why?
| | src-Family Kinases | 1 | 2014 | 88 | 0.430 |
Why?
| | Cardiovascular Agents | 1 | 2014 | 125 | 0.420 |
Why?
| | Valsartan | 3 | 2023 | 22 | 0.420 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1215 | 0.420 |
Why?
| | Genes, Dominant | 12 | 2007 | 94 | 0.420 |
Why?
| | Cytoskeleton | 7 | 2020 | 177 | 0.420 |
Why?
| | Genetic Association Studies | 5 | 2021 | 345 | 0.400 |
Why?
| | Disease Management | 4 | 2021 | 563 | 0.390 |
Why?
| | Disease Progression | 5 | 2021 | 2392 | 0.390 |
Why?
| | Human Genome Project | 1 | 2011 | 14 | 0.380 |
Why?
| | Myocardial Infarction | 2 | 2019 | 929 | 0.380 |
Why?
| | Nuclear Proteins | 2 | 2009 | 593 | 0.370 |
Why?
| | Gene Expression Regulation | 4 | 2020 | 2324 | 0.370 |
Why?
| | Risk Assessment | 11 | 2020 | 2975 | 0.350 |
Why?
| | Genetic Linkage | 10 | 2001 | 297 | 0.340 |
Why?
| | Cell Differentiation | 2 | 2017 | 1699 | 0.340 |
Why?
| | Genome, Human | 1 | 2011 | 352 | 0.330 |
Why?
| | Desmoplakins | 2 | 2020 | 19 | 0.330 |
Why?
| | Cells, Cultured | 9 | 2021 | 3897 | 0.320 |
Why?
| | Muscular Dystrophies | 2 | 2018 | 36 | 0.320 |
Why?
| | Italy | 13 | 2020 | 92 | 0.310 |
Why?
| | Molecular Biology | 4 | 1997 | 56 | 0.310 |
Why?
| | Desmosomes | 3 | 2019 | 20 | 0.310 |
Why?
| | Chromosome Mapping | 8 | 1997 | 490 | 0.310 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2020 | 447 | 0.290 |
Why?
| | Lamins | 2 | 2004 | 4 | 0.290 |
Why?
| | Myosin Heavy Chains | 3 | 2013 | 177 | 0.280 |
Why?
| | Fibrosis | 4 | 2023 | 454 | 0.270 |
Why?
| | Repressor Proteins | 1 | 2009 | 368 | 0.270 |
Why?
| | Genotype | 6 | 2022 | 1775 | 0.260 |
Why?
| | Myocarditis | 5 | 2022 | 93 | 0.260 |
Why?
| | Indazoles | 2 | 2022 | 58 | 0.250 |
Why?
| | Risk Factors | 12 | 2022 | 8637 | 0.250 |
Why?
| | Animals, Newborn | 5 | 2022 | 777 | 0.250 |
Why?
| | Ventricular Myosins | 1 | 2005 | 33 | 0.250 |
Why?
| | Heart Transplantation | 7 | 2020 | 667 | 0.250 |
Why?
| | Adolescent | 26 | 2023 | 17829 | 0.250 |
Why?
| | Materials Testing | 2 | 2019 | 338 | 0.240 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 2211 | 0.240 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2023 | 2 | 0.230 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1801 | 0.230 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2004 | 16 | 0.230 |
Why?
| | Heterozygote | 7 | 2021 | 251 | 0.230 |
Why?
| | Desmin | 2 | 2018 | 31 | 0.220 |
Why?
| | Prealbumin | 1 | 2023 | 22 | 0.220 |
Why?
| | X Chromosome | 8 | 2001 | 47 | 0.220 |
Why?
| | Tachycardia | 1 | 2023 | 50 | 0.220 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2004 | 474 | 0.220 |
Why?
| | NAD | 1 | 2023 | 64 | 0.220 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2016 | 175 | 0.220 |
Why?
| | Ventricular Function, Right | 2 | 2023 | 252 | 0.210 |
Why?
| | Genetic Markers | 4 | 2018 | 322 | 0.210 |
Why?
| | Progeria | 1 | 2022 | 3 | 0.210 |
Why?
| | Ethylenediamines | 1 | 2022 | 6 | 0.210 |
Why?
| | Point Mutation | 4 | 2011 | 217 | 0.210 |
Why?
| | Retrospective Studies | 15 | 2023 | 12544 | 0.210 |
Why?
| | Tachycardia, Ventricular | 3 | 2008 | 153 | 0.200 |
Why?
| | Myocardial Contraction | 4 | 2023 | 312 | 0.200 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 40 | 0.200 |
Why?
| | Chromosomes, Human, Pair 9 | 3 | 1997 | 43 | 0.200 |
Why?
| | Microtechnology | 1 | 2021 | 5 | 0.190 |
Why?
| | Chagas Cardiomyopathy | 1 | 2021 | 22 | 0.190 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2022 | 42 | 0.190 |
Why?
| | Chagas Disease | 1 | 2021 | 34 | 0.190 |
Why?
| | Heart Murmurs | 1 | 2021 | 11 | 0.190 |
Why?
| | Genomics | 2 | 2017 | 641 | 0.190 |
Why?
| | ADAM10 Protein | 1 | 2021 | 28 | 0.190 |
Why?
| | Extracellular Matrix | 2 | 2022 | 436 | 0.180 |
Why?
| | Time Factors | 10 | 2019 | 6125 | 0.180 |
Why?
| | Gamma Rays | 1 | 2021 | 48 | 0.180 |
Why?
| | Neuromuscular Diseases | 1 | 2002 | 89 | 0.180 |
Why?
| | Actinin | 1 | 2020 | 13 | 0.180 |
Why?
| | Mice | 12 | 2022 | 14935 | 0.180 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 3 | 2017 | 10 | 0.180 |
Why?
| | Combined Modality Therapy | 2 | 2021 | 1126 | 0.180 |
Why?
| | Mechanical Phenomena | 1 | 2021 | 80 | 0.180 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 73 | 0.180 |
Why?
| | Heart Diseases | 1 | 2023 | 330 | 0.180 |
Why?
| | Epidermolysis Bullosa Simplex | 1 | 2020 | 9 | 0.180 |
Why?
| | Myofibroblasts | 1 | 2021 | 116 | 0.170 |
Why?
| | Ectodermal Dysplasia | 1 | 2020 | 15 | 0.170 |
Why?
| | Heart Conduction System | 3 | 2016 | 82 | 0.170 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2021 | 80 | 0.170 |
Why?
| | Elastic Modulus | 5 | 2022 | 116 | 0.170 |
Why?
| | Double-Blind Method | 3 | 2021 | 1663 | 0.170 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 29 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 128 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2018 | 441 | 0.170 |
Why?
| | Elasticity | 2 | 2017 | 190 | 0.170 |
Why?
| | Nanostructures | 1 | 2020 | 96 | 0.170 |
Why?
| | Nanotechnology | 1 | 2020 | 113 | 0.170 |
Why?
| | Ankyrins | 1 | 2019 | 7 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 168 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 198 | 0.170 |
Why?
| | Atrial Fibrillation | 1 | 2003 | 325 | 0.160 |
Why?
| | Muscular Diseases | 1 | 2000 | 105 | 0.160 |
Why?
| | Aged | 24 | 2022 | 19122 | 0.160 |
Why?
| | Membrane Proteins | 2 | 2021 | 1022 | 0.160 |
Why?
| | Gene Deletion | 2 | 1997 | 356 | 0.160 |
Why?
| | Immunity, Cellular | 2 | 2018 | 249 | 0.160 |
Why?
| | Biopsy | 4 | 2022 | 1045 | 0.160 |
Why?
| | Actin Cytoskeleton | 2 | 2021 | 93 | 0.160 |
Why?
| | Alleles | 1 | 2021 | 791 | 0.160 |
Why?
| | Hypertrophy, Left Ventricular | 2 | 2023 | 103 | 0.160 |
Why?
| | Coculture Techniques | 1 | 2019 | 201 | 0.160 |
Why?
| | Cell Nucleus | 3 | 2019 | 554 | 0.160 |
Why?
| | Cytochalasin D | 2 | 2015 | 5 | 0.160 |
Why?
| | DNA | 2 | 2016 | 1351 | 0.150 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 212 | 0.150 |
Why?
| | Contrast Media | 1 | 2021 | 353 | 0.150 |
Why?
| | Sodium Channels | 2 | 2011 | 62 | 0.150 |
Why?
| | Young Adult | 10 | 2021 | 10478 | 0.150 |
Why?
| | Skin Physiological Phenomena | 1 | 2017 | 26 | 0.150 |
Why?
| | Intermediate Filaments | 1 | 2017 | 46 | 0.150 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 147 | 0.150 |
Why?
| | Muscle, Skeletal | 6 | 2005 | 1472 | 0.150 |
Why?
| | Cardiac Imaging Techniques | 1 | 2017 | 21 | 0.150 |
Why?
| | Family Health | 2 | 2011 | 194 | 0.150 |
Why?
| | Ion Channels | 1 | 2018 | 123 | 0.150 |
Why?
| | Transcriptome | 2 | 2020 | 728 | 0.140 |
Why?
| | Gelatin | 1 | 2017 | 36 | 0.140 |
Why?
| | Prevalence | 8 | 2021 | 2252 | 0.140 |
Why?
| | Mechanotransduction, Cellular | 1 | 2018 | 97 | 0.140 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 234 | 0.140 |
Why?
| | MicroRNAs | 2 | 2020 | 601 | 0.140 |
Why?
| | Vasodilator Agents | 4 | 1988 | 305 | 0.140 |
Why?
| | Internationality | 1 | 2017 | 144 | 0.140 |
Why?
| | Odds Ratio | 2 | 2017 | 954 | 0.140 |
Why?
| | Cell Proliferation | 4 | 2021 | 2199 | 0.140 |
Why?
| | Troponin T | 2 | 2013 | 49 | 0.140 |
Why?
| | DNA Damage | 1 | 2019 | 357 | 0.140 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 92 | 0.140 |
Why?
| | Cross-Sectional Studies | 4 | 2019 | 4407 | 0.140 |
Why?
| | Exome | 2 | 2017 | 201 | 0.140 |
Why?
| | Keratinocytes | 1 | 2017 | 216 | 0.130 |
Why?
| | Multigene Family | 1 | 2017 | 193 | 0.130 |
Why?
| | Shear Strength | 1 | 2016 | 65 | 0.130 |
Why?
| | Proteomics | 1 | 2022 | 844 | 0.130 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1440 | 0.130 |
Why?
| | Wolff-Parkinson-White Syndrome | 1 | 2016 | 16 | 0.130 |
Why?
| | Chromosomes, Human, Pair 14 | 4 | 1996 | 16 | 0.130 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 344 | 0.130 |
Why?
| | Nanofibers | 1 | 2015 | 19 | 0.130 |
Why?
| | Treatment Failure | 1 | 2017 | 332 | 0.130 |
Why?
| | Polyesters | 1 | 2015 | 64 | 0.130 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2009 | 288 | 0.130 |
Why?
| | Chromosomes | 1 | 1995 | 87 | 0.130 |
Why?
| | Follow-Up Studies | 13 | 2021 | 4427 | 0.120 |
Why?
| | DNA Methylation | 1 | 2019 | 496 | 0.120 |
Why?
| | Genotyping Techniques | 2 | 2012 | 69 | 0.120 |
Why?
| | Logistic Models | 2 | 2017 | 1844 | 0.120 |
Why?
| | Spectrum Analysis | 1 | 2015 | 81 | 0.120 |
Why?
| | Cell Membrane | 1 | 2018 | 679 | 0.120 |
Why?
| | Propanolamines | 2 | 2009 | 90 | 0.120 |
Why?
| | Electrocardiography, Ambulatory | 3 | 2015 | 54 | 0.120 |
Why?
| | Catheter Ablation | 2 | 2014 | 291 | 0.120 |
Why?
| | Heart Aneurysm | 1 | 1994 | 8 | 0.110 |
Why?
| | Polymerase Chain Reaction | 7 | 2008 | 995 | 0.110 |
Why?
| | Cell Culture Techniques | 1 | 2016 | 344 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 733 | 0.110 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 171 | 0.110 |
Why?
| | Autophagy | 1 | 2016 | 234 | 0.110 |
Why?
| | DNA, Mitochondrial | 3 | 2004 | 182 | 0.110 |
Why?
| | Genetics | 1 | 2013 | 27 | 0.110 |
Why?
| | Molecular Sequence Data | 6 | 2014 | 2791 | 0.110 |
Why?
| | Accessory Atrioventricular Bundle | 1 | 2013 | 11 | 0.110 |
Why?
| | Cell Enlargement | 1 | 2013 | 5 | 0.110 |
Why?
| | Child | 15 | 2023 | 18366 | 0.110 |
Why?
| | Giant Cells | 1 | 2013 | 21 | 0.110 |
Why?
| | Action Potentials | 1 | 2016 | 406 | 0.110 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 1988 | 0.110 |
Why?
| | Monitoring, Physiologic | 2 | 2021 | 248 | 0.110 |
Why?
| | Cohort Studies | 7 | 2022 | 4903 | 0.110 |
Why?
| | Heart Rate | 2 | 2016 | 705 | 0.110 |
Why?
| | Tachycardia, Supraventricular | 1 | 2013 | 42 | 0.110 |
Why?
| | Atrioventricular Block | 1 | 2013 | 37 | 0.110 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 133 | 0.100 |
Why?
| | Biomarkers | 2 | 2023 | 3418 | 0.100 |
Why?
| | Prospective Studies | 9 | 2023 | 6218 | 0.100 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2021 | 106 | 0.100 |
Why?
| | American Heart Association | 1 | 2013 | 264 | 0.100 |
Why?
| | Survival Rate | 6 | 2021 | 1644 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1523 | 0.100 |
Why?
| | Particle Size | 1 | 2013 | 317 | 0.100 |
Why?
| | Surface Properties | 1 | 2013 | 387 | 0.100 |
Why?
| | Electrophysiological Phenomena | 1 | 2012 | 48 | 0.100 |
Why?
| | Biomechanical Phenomena | 3 | 2022 | 672 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2014 | 369 | 0.100 |
Why?
| | Nuclear Lamina | 2 | 2020 | 10 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 4 | 2015 | 817 | 0.100 |
Why?
| | Sequence Analysis, DNA | 2 | 2012 | 729 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 4 | 2021 | 3053 | 0.100 |
Why?
| | Penetrance | 1 | 2011 | 27 | 0.100 |
Why?
| | Graft Rejection | 2 | 2004 | 516 | 0.100 |
Why?
| | Chromosome Disorders | 3 | 1997 | 35 | 0.100 |
Why?
| | Sensitivity and Specificity | 6 | 2015 | 1700 | 0.100 |
Why?
| | Sex Chromosome Aberrations | 3 | 1997 | 51 | 0.100 |
Why?
| | Equipment Design | 1 | 2013 | 511 | 0.090 |
Why?
| | Chromosome Aberrations | 3 | 1997 | 138 | 0.090 |
Why?
| | Nanoparticles | 1 | 2014 | 313 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2015 | 1400 | 0.090 |
Why?
| | Immunosuppressive Agents | 2 | 2004 | 648 | 0.090 |
Why?
| | Syndrome | 1 | 2011 | 336 | 0.090 |
Why?
| | Family | 2 | 2014 | 590 | 0.090 |
Why?
| | Robotics | 1 | 2011 | 75 | 0.090 |
Why?
| | Diagnosis, Differential | 4 | 2020 | 1355 | 0.090 |
Why?
| | Sarcoidosis | 1 | 2012 | 135 | 0.090 |
Why?
| | Cell Division | 1 | 2012 | 759 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 4718 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 1 | 2014 | 414 | 0.090 |
Why?
| | Gene Frequency | 3 | 2017 | 481 | 0.090 |
Why?
| | Genetic Counseling | 2 | 2009 | 65 | 0.090 |
Why?
| | United States | 8 | 2021 | 12211 | 0.080 |
Why?
| | Chromosomes, Human, Pair 3 | 3 | 2004 | 49 | 0.080 |
Why?
| | Sequence Deletion | 3 | 2014 | 168 | 0.080 |
Why?
| | RNA | 3 | 2023 | 810 | 0.080 |
Why?
| | Global Health | 2 | 2014 | 288 | 0.080 |
Why?
| | Disease-Free Survival | 3 | 2015 | 623 | 0.080 |
Why?
| | Enterovirus | 3 | 1994 | 72 | 0.080 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1635 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2022 | 9105 | 0.080 |
Why?
| | Cardiomyopathy, Restrictive | 4 | 1999 | 9 | 0.080 |
Why?
| | Organic Cation Transport Proteins | 1 | 2008 | 26 | 0.080 |
Why?
| | Carnitine | 1 | 2008 | 62 | 0.070 |
Why?
| | Amiodarone | 4 | 2011 | 23 | 0.070 |
Why?
| | Endothelin-1 | 1 | 2009 | 167 | 0.070 |
Why?
| | Consensus | 2 | 2019 | 534 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2021 | 3549 | 0.070 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 1997 | 67 | 0.070 |
Why?
| | Retinitis Pigmentosa | 1 | 2006 | 16 | 0.070 |
Why?
| | Child, Preschool | 6 | 2017 | 9086 | 0.070 |
Why?
| | Endocardium | 3 | 1999 | 30 | 0.070 |
Why?
| | Myopia | 1 | 2006 | 36 | 0.070 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 3 | 2014 | 26 | 0.060 |
Why?
| | Europe | 2 | 2018 | 336 | 0.060 |
Why?
| | Autoimmune Diseases | 3 | 2001 | 392 | 0.060 |
Why?
| | Gene Expression | 3 | 2008 | 1422 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2018 | 3008 | 0.060 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 62 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2013 | 6364 | 0.060 |
Why?
| | Prenatal Diagnosis | 1 | 2006 | 168 | 0.060 |
Why?
| | Conserved Sequence | 1 | 2005 | 218 | 0.060 |
Why?
| | Hemodynamics | 9 | 1992 | 1014 | 0.060 |
Why?
| | NIH 3T3 Cells | 2 | 2015 | 137 | 0.060 |
Why?
| | Virus Diseases | 3 | 1998 | 196 | 0.060 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1197 | 0.060 |
Why?
| | Homozygote | 2 | 2015 | 188 | 0.060 |
Why?
| | Primary Prevention | 2 | 2016 | 171 | 0.060 |
Why?
| | Cell Shape | 2 | 2015 | 54 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 934 | 0.060 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 36 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 262 | 0.060 |
Why?
| | Haplotypes | 3 | 2013 | 453 | 0.060 |
Why?
| | Cataract | 1 | 2006 | 185 | 0.060 |
Why?
| | Transplantation, Homologous | 1 | 2004 | 387 | 0.050 |
Why?
| | Transforming Growth Factors | 1 | 2023 | 3 | 0.050 |
Why?
| | Mass Screening | 1 | 2010 | 1011 | 0.050 |
Why?
| | Antigens, CD | 2 | 2017 | 443 | 0.050 |
Why?
| | Pregnancy | 3 | 2022 | 5527 | 0.050 |
Why?
| | Codon, Nonsense | 1 | 2023 | 37 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2023 | 156 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 14 | 1 | 2022 | 6 | 0.050 |
Why?
| | Dogs | 1 | 2023 | 337 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 82 | 0.050 |
Why?
| | Glycolysis | 1 | 2023 | 227 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 1729 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 222 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2022 | 96 | 0.050 |
Why?
| | RNA, Messenger | 3 | 2020 | 2558 | 0.050 |
Why?
| | Genetic Background | 1 | 2021 | 8 | 0.050 |
Why?
| | Optical Tweezers | 1 | 2021 | 18 | 0.050 |
Why?
| | Models, Biological | 2 | 2021 | 1630 | 0.050 |
Why?
| | Pyrroles | 1 | 2022 | 183 | 0.050 |
Why?
| | Metoprolol | 2 | 1999 | 37 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 2640 | 0.050 |
Why?
| | Nanotubes | 1 | 2021 | 41 | 0.050 |
Why?
| | Ephrin-B2 | 1 | 2021 | 36 | 0.050 |
Why?
| | Apoptosis | 2 | 2021 | 2371 | 0.050 |
Why?
| | Base Sequence | 5 | 2014 | 2118 | 0.050 |
Why?
| | Computational Biology | 2 | 2015 | 531 | 0.050 |
Why?
| | Electric Conductivity | 1 | 2020 | 88 | 0.050 |
Why?
| | Exercise Test | 4 | 2017 | 545 | 0.050 |
Why?
| | Gadolinium | 1 | 2021 | 75 | 0.040 |
Why?
| | Ferric Compounds | 1 | 2020 | 40 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2023 | 927 | 0.040 |
Why?
| | Transfection | 2 | 2017 | 870 | 0.040 |
Why?
| | RNA, Viral | 2 | 1994 | 565 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 449 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2022 | 473 | 0.040 |
Why?
| | HeLa Cells | 2 | 2015 | 562 | 0.040 |
Why?
| | Denmark | 1 | 2019 | 39 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 396 | 0.040 |
Why?
| | Brazil | 1 | 2019 | 90 | 0.040 |
Why?
| | Maleimides | 1 | 2019 | 24 | 0.040 |
Why?
| | Cell Plasticity | 1 | 2019 | 23 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 176 | 0.040 |
Why?
| | Infant | 4 | 2020 | 7937 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 285 | 0.040 |
Why?
| | E2F Transcription Factors | 1 | 2019 | 55 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 855 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2019 | 34 | 0.040 |
Why?
| | Regeneration | 1 | 2020 | 160 | 0.040 |
Why?
| | Heterochromatin | 1 | 2019 | 32 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 153 | 0.040 |
Why?
| | Carbazoles | 1 | 1999 | 78 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1317 | 0.040 |
Why?
| | CpG Islands | 1 | 2019 | 117 | 0.040 |
Why?
| | Canada | 1 | 2019 | 322 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 897 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 706 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2021 | 2770 | 0.040 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2018 | 14 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 460 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2013 | 1080 | 0.040 |
Why?
| | Ultrasonography | 2 | 1999 | 633 | 0.040 |
Why?
| | Alginates | 1 | 2018 | 44 | 0.040 |
Why?
| | Intercellular Junctions | 1 | 2017 | 33 | 0.040 |
Why?
| | Age Factors | 2 | 2016 | 2891 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2022 | 635 | 0.040 |
Why?
| | Collagen | 1 | 2020 | 416 | 0.040 |
Why?
| | beta Catenin | 1 | 2019 | 220 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 2 | 2018 | 796 | 0.040 |
Why?
| | Aorta | 1 | 2000 | 390 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 262 | 0.040 |
Why?
| | Indoles | 1 | 2019 | 306 | 0.040 |
Why?
| | Multilevel Analysis | 1 | 2017 | 26 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 503 | 0.040 |
Why?
| | Netherlands | 1 | 2017 | 64 | 0.040 |
Why?
| | Biocompatible Materials | 1 | 2020 | 369 | 0.030 |
Why?
| | Incidence | 3 | 2011 | 2316 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 1893 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 867 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 4524 | 0.030 |
Why?
| | Bundle-Branch Block | 1 | 2016 | 29 | 0.030 |
Why?
| | Molecular Dynamics Simulation | 1 | 2018 | 201 | 0.030 |
Why?
| | Gene Editing | 1 | 2017 | 57 | 0.030 |
Why?
| | Membrane Potentials | 1 | 2017 | 249 | 0.030 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 78 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2017 | 189 | 0.030 |
Why?
| | Heredity | 1 | 2015 | 12 | 0.030 |
Why?
| | Sodium | 1 | 2017 | 182 | 0.030 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2017 | 174 | 0.030 |
Why?
| | Recovery of Function | 1 | 2019 | 572 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 495 | 0.030 |
Why?
| | Lod Score | 1 | 1995 | 65 | 0.030 |
Why?
| | Genes, Recessive | 1 | 1995 | 73 | 0.030 |
Why?
| | Cadherins | 1 | 2017 | 176 | 0.030 |
Why?
| | Exons | 2 | 2008 | 302 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2015 | 192 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 1995 | 141 | 0.030 |
Why?
| | Introns | 1 | 1996 | 227 | 0.030 |
Why?
| | Enterovirus Infections | 2 | 1994 | 160 | 0.030 |
Why?
| | Mutagenesis | 1 | 2015 | 170 | 0.030 |
Why?
| | Genes, Immunoglobulin | 1 | 1994 | 26 | 0.030 |
Why?
| | Viscosity | 1 | 2015 | 81 | 0.030 |
Why?
| | Quality of Life | 2 | 2023 | 2359 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 95 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 591 | 0.030 |
Why?
| | Cytochalasins | 1 | 2014 | 3 | 0.030 |
Why?
| | RNA Splicing | 1 | 1996 | 245 | 0.030 |
Why?
| | Tubulin | 1 | 2015 | 123 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2015 | 368 | 0.030 |
Why?
| | Body Temperature | 1 | 2014 | 208 | 0.030 |
Why?
| | Major Histocompatibility Complex | 1 | 1994 | 219 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 1994 | 94 | 0.030 |
Why?
| | Cause of Death | 1 | 2015 | 363 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1994 | 80 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 277 | 0.030 |
Why?
| | Cardiac Myosins | 1 | 2013 | 26 | 0.030 |
Why?
| | Turner Syndrome | 1 | 1994 | 45 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 1994 | 201 | 0.030 |
Why?
| | Ventricular Fibrillation | 1 | 2013 | 51 | 0.030 |
Why?
| | Skin | 1 | 2017 | 659 | 0.030 |
Why?
| | Formaldehyde | 1 | 2013 | 46 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2586 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2542 | 0.030 |
Why?
| | Electrophysiology | 1 | 2013 | 201 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 448 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1034 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 1022 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 2012 | 17 | 0.030 |
Why?
| | Mediastinal Diseases | 1 | 2012 | 10 | 0.030 |
Why?
| | Pacemaker, Artificial | 1 | 2013 | 107 | 0.020 |
Why?
| | Patient Selection | 1 | 2015 | 642 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 924 | 0.020 |
Why?
| | Blood Pressure | 2 | 2016 | 1537 | 0.020 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1992 | 125 | 0.020 |
Why?
| | Immune System | 1 | 1992 | 173 | 0.020 |
Why?
| | Antibody Formation | 1 | 1992 | 267 | 0.020 |
Why?
| | Observer Variation | 1 | 2011 | 297 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 2725 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2013 | 696 | 0.020 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 954 | 0.020 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2009 | 10 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2010 | 217 | 0.020 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2009 | 21 | 0.020 |
Why?
| | Metalloendopeptidases | 1 | 2009 | 55 | 0.020 |
Why?
| | Autoimmunity | 1 | 1994 | 818 | 0.020 |
Why?
| | Endothelins | 1 | 2009 | 61 | 0.020 |
Why?
| | Solute Carrier Family 22 Member 5 | 1 | 2008 | 4 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2009 | 245 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 1988 | 115 | 0.020 |
Why?
| | Cricetulus | 1 | 2008 | 97 | 0.020 |
Why?
| | CHO Cells | 1 | 2008 | 138 | 0.020 |
Why?
| | Death, Sudden | 1 | 1987 | 27 | 0.020 |
Why?
| | Cricetinae | 1 | 2008 | 254 | 0.020 |
Why?
| | Amyloidosis | 1 | 1987 | 36 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2007 | 24 | 0.020 |
Why?
| | Algorithms | 1 | 2013 | 1474 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2006 | 27 | 0.020 |
Why?
| | Electroretinography | 1 | 2006 | 40 | 0.020 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 34 | 0.020 |
Why?
| | Visual Fields | 1 | 2006 | 77 | 0.020 |
Why?
| | Models, Genetic | 1 | 2009 | 565 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2006 | 102 | 0.020 |
Why?
| | Terminology as Topic | 2 | 1999 | 187 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2007 | 398 | 0.020 |
Why?
| | Societies, Medical | 1 | 2009 | 677 | 0.020 |
Why?
| | Antimetabolites | 1 | 2004 | 21 | 0.020 |
Why?
| | Growth Inhibitors | 1 | 2004 | 44 | 0.020 |
Why?
| | Coxsackievirus Infections | 1 | 1984 | 12 | 0.020 |
Why?
| | Azathioprine | 1 | 2004 | 49 | 0.020 |
Why?
| | Everolimus | 1 | 2004 | 61 | 0.010 |
Why?
| | Calcineurin Inhibitors | 1 | 2004 | 58 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2005 | 338 | 0.010 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 77 | 0.010 |
Why?
| | Cyclosporine | 1 | 2004 | 161 | 0.010 |
Why?
| | Chromatography, Liquid | 1 | 2005 | 348 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4091 | 0.010 |
Why?
| | Tacrolimus | 1 | 2004 | 134 | 0.010 |
Why?
| | Sirolimus | 1 | 2004 | 181 | 0.010 |
Why?
| | Comorbidity | 1 | 2008 | 1458 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 797 | 0.010 |
Why?
| | Captopril | 1 | 1983 | 11 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 731 | 0.010 |
Why?
| | Proline | 1 | 1983 | 72 | 0.010 |
Why?
| | Probability | 1 | 2003 | 291 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 387 | 0.010 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 359 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2004 | 499 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 1992 | 1737 | 0.010 |
Why?
| | Risk | 1 | 2003 | 815 | 0.010 |
Why?
| | Enterovirus B, Human | 2 | 1993 | 24 | 0.010 |
Why?
| | Chronic Disease | 1 | 1985 | 1593 | 0.010 |
Why?
| | Echocardiography, Doppler | 1 | 1999 | 93 | 0.010 |
Why?
| | World Health Organization | 1 | 1998 | 103 | 0.010 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1999 | 180 | 0.010 |
Why?
| | Survival Analysis | 2 | 1991 | 1220 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 1999 | 441 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 1999 | 588 | 0.010 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1995 | 81 | 0.010 |
Why?
| | Organ Specificity | 1 | 1995 | 270 | 0.010 |
Why?
| | Receptors, Interleukin | 1 | 1994 | 39 | 0.010 |
Why?
| | Gene Amplification | 1 | 1994 | 97 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1994 | 45 | 0.010 |
Why?
| | Genome, Viral | 1 | 1994 | 119 | 0.010 |
Why?
| | Fathers | 1 | 1994 | 45 | 0.010 |
Why?
| | Virology | 1 | 1993 | 19 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1993 | 152 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1993 | 168 | 0.010 |
Why?
| | Interleukins | 1 | 1994 | 236 | 0.010 |
Why?
| | Iodocyanopindolol | 1 | 1992 | 11 | 0.010 |
Why?
| | Pindolol | 1 | 1992 | 15 | 0.010 |
Why?
| | Neuropeptide Y | 1 | 1992 | 13 | 0.010 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1992 | 27 | 0.010 |
Why?
| | Adenylyl Cyclases | 1 | 1992 | 82 | 0.010 |
Why?
| | Species Specificity | 1 | 1993 | 547 | 0.010 |
Why?
| | Catecholamines | 1 | 1992 | 95 | 0.010 |
Why?
| | Isoproterenol | 1 | 1992 | 107 | 0.010 |
Why?
| | Autoantigens | 1 | 1994 | 397 | 0.010 |
Why?
| | Complement System Proteins | 1 | 1994 | 285 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1133 | 0.010 |
Why?
| | DNA, Viral | 1 | 1993 | 350 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1994 | 620 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1995 | 1317 | 0.010 |
Why?
| | Felodipine | 1 | 1988 | 4 | 0.010 |
Why?
| | Nitrendipine | 1 | 1988 | 13 | 0.010 |
Why?
| | Nisoldipine | 1 | 1988 | 6 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1999 | 5035 | 0.010 |
Why?
| | Nicardipine | 1 | 1988 | 6 | 0.010 |
Why?
| | Diltiazem | 1 | 1988 | 23 | 0.010 |
Why?
| | Nifedipine | 1 | 1988 | 29 | 0.000 |
Why?
| | Verapamil | 1 | 1988 | 32 | 0.000 |
Why?
| | Statistics as Topic | 1 | 1989 | 294 | 0.000 |
Why?
| | Autoantibodies | 1 | 1994 | 1354 | 0.000 |
Why?
| | Cardiomyopathy, Alcoholic | 1 | 1985 | 1 | 0.000 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1985 | 64 | 0.000 |
Why?
| | Physical Exertion | 1 | 1986 | 211 | 0.000 |
Why?
| | Heart Septal Defects | 1 | 1984 | 10 | 0.000 |
Why?
| | Cardiac Output | 1 | 1984 | 143 | 0.000 |
Why?
| | Cardiac Catheterization | 1 | 1987 | 535 | 0.000 |
Why?
| | Vascular Resistance | 1 | 1984 | 338 | 0.000 |
Why?
| | Coronary Disease | 1 | 1984 | 347 | 0.000 |
Why?
| | Ethanol | 1 | 1985 | 548 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1984 | 522 | 0.000 |
Why?
| | Hypertension | 1 | 1985 | 1059 | 0.000 |
Why?
|
|
Mestroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|